Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond

Title:Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond

Volume: 24 Issue: 4

Author(s): Patrick Proctor, Massoud A. Leesar and Arka Chatterjee*

Affiliation:

• Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL,United States

Keywords: Thrombolysis, acute myocardial infarction, catheter directed thrombolysis, pulmonary embolism, acute ischemic stroke, thrombolytic therapy.

Abstract: Thrombolytic therapy kick-started the era of modern cardiology but in the last few decades it has been largely supplanted by primary percutaneous coronary intervention (PCI) as the go-to treatment for acute myocardial infarction. However, these agents remain important for vast populations without access to primary PCI and acute ischemic stroke. More innovative uses have recently come up for the treatment of a variety of conditions. This article summarizes the history, evidence base and current use of thrombolytics in cardiovascular disease.

Cite this article as:

Proctor Patrick , Leesar A. Massoud and Chatterjee Arka *, Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond, Current Pharmaceutical Design 2018; 24 (4) . https://dx.doi.org/10.2174/1381612824666171227211623